Virtus Fund Advisers’s Anika Therapeutics ANIK Stock Holding History

Virtus Fund Advisers’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$44.8K	Buy	2,724 +94	+4%	+$1.85K	0.14%	75
2024 Q3	$65K	Hold	2,630	–	–	0.26%	47
2024 Q2	$66.6K	Buy	2,630 +71	+3%	+$1.84K	0.26%	40
2024 Q1	$65K	Buy	+2,559	New	+$61.9K	0.23%	48
2023 Q4	–	Sell	-3,490	Closed	-$65K	–	106
2023 Q3	$65K	Hold	3,490	–	–	0.46%	31
2023 Q2	$90.7K	Hold	3,490	–	–	0.64%	19
2023 Q1	$100K	Hold	3,490	–	–	0.7%	17
2022 Q4	$103K	Buy	+3,490	New	+$99.3K	0.74%	14
2015 Q2	–	Sell	-20,836	Closed	-$858K	–	855
2015 Q1	$858K	Sell	20,836 -1,931	-8%	-$78.1K	0.01%	364
2014 Q4	$928K	Buy	22,767 +110	+0.5%	+$4.3K	0.01%	376
2014 Q3	$831K	Sell	22,657 -1,071	-5%	-$46.3K	0.01%	403
2014 Q2	$1.1M	Buy	+23,728	New	+$1.06M	0.01%	439

Other funds holding ANIK

Trigran Investments Northbrook, Illinois $418M AUM 3.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AFA

Alta Fundamental Advisers New York $265M AUM 98.61% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Capital Management Glen Allen, Virginia $585M AUM 5.18% 1-Year Est. Return

Virtus Fund Advisers's ANIK Position: Q4 2024 in Review

Virtus Fund Advisers increased its Anika Therapeutics (ANIK) stake by 3.6% in Q4 2024, buying an estimated $1.85K and bringing the position to 2,724 shares worth $44.8K. The position accounts for 0.14% of the portfolio, ranked #75.

Virtus Fund Advisers first reported a position in ANIK in Q2 2014 and has held it in 12 quarters since. The position peaked at $1.1M in Q2 2014. 109 funds tracked by Wall St. Rank hold ANIK as of Q4 2024.

Virtus Fund Advisers held 2,724 shares of Anika Therapeutics worth $44.8K as of Q4 2024.
Virtus Fund Advisers bought 94 Anika Therapeutics shares in Q4 2024, an estimated $1.85K.
Anika Therapeutics made up 0.14% of Virtus Fund Advisers's portfolio in Q4 2024, its #75 holding.
Virtus Fund Advisers first reported a position in Anika Therapeutics in Q2 2014 and has held it in 12 quarters since.
Virtus Fund Advisers's Anika Therapeutics position peaked at $1.1M in Q2 2014.
109 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2024.

Based on Virtus Fund Advisers's 13F filing for Q4 2024, filed 14 Feb 2025.